Compare NL & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NL | PALI |
|---|---|---|
| Founded | 1891 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.9M | 311.8M |
| IPO Year | N/A | N/A |
| Metric | NL | PALI |
|---|---|---|
| Price | $6.11 | $1.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 73.6K | ★ 5.9M |
| Earning Date | 03-05-2026 | 11-10-2025 |
| Dividend Yield | ★ 9.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $159,004,000.00 | N/A |
| Revenue This Year | $15.75 | N/A |
| Revenue Next Year | $2.44 | N/A |
| P/E Ratio | $31.75 | ★ N/A |
| Revenue Growth | ★ 5.52 | N/A |
| 52 Week Low | $5.04 | $0.53 |
| 52 Week High | $9.27 | $2.64 |
| Indicator | NL | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 39.90 |
| Support Level | $5.95 | $1.64 |
| Resistance Level | $6.45 | $1.96 |
| Average True Range (ATR) | 0.40 | 0.16 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 49.19 | 4.35 |
NL Industries Inc is a holding company that operates in the component products industry. Through its subsidiary, it manufactures engineered components that are sold to a range of industries, including recreational transportation, postal, office and institutional furniture, cabinetry, tool storage, healthcare, gas stations and vending equipment. It also produces a precision ball bearing slide, security products, and ergonomic computer support systems. The company derives majority of its revenue from Europe.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.